Arkolith/Insider Trading/SGMT/Form 4

Happel David

President & CEO, DirectorSagimet Biosciences Inc. (SGMT) · full profile →Form 4 · filed Jul 20, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 18, 2023Disposed to issuer(D)1.0M—$00
Jul 18, 2023Grant(A)1.0M—$01.0M

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-23-082722) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML